DTU
DTU

Dr Olorunsola Agbaje

Olorunsola Agbaje 2014

Position:Senior Medical Statistician

Telephone:01865 857116

Email:olorunsola.agbaje@dtu.ox.ac.uk

Dr Olorunsola (Shola)  Agbaje is a Senior Medical Statistician at the University of Oxford Diabetes Trials Unit (DTU). He joined the DTU in March 2013 where he serves as the statistical lead in the Translational Research Group (TRG) and  the Oxford statistical lead for the MASTERMIND study.

Prior to joining the DTU, he was a Senior Medical Statistician in the  Department of Research Oncology at Guy’s Hospital, London. At Guy’s, he provided statistical expertise and leadership for various research teams, with a particular focus on clinical trials for the evaluation of surgical devices for breast cancer surgeries and modelling prediction of breast cancer survival using clinical, biochemical and gene expression data.

Shola was a member of the Metabolic Modelling Group at the University of Cambridge. During this time, he worked on a number of glucose control projects, CLINICIL for monitoring blood glucose for critically ill patients, artificial pancreas for the treatment of subjects with type I diabetes and a number of advanced statistical models for estimating insulin sensitivity and glucose effectiveness in type II diabetes.

Research interests have focused mainly on advanced statistical modelling techniques and their medical applications, with particular interests in design and analysis of clinical experiments, statistical models for intensive longitudinal data and event history analysis.

Latest publications

Manuscript
Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA et al.
J Diabetes Complications 2019;33:69-74

Conference abstract
The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes
C. Ballav et al.
Diabetelogia 2018;61:S387

Manuscript
Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa et al.
Diabet Med. 2018;35:72-77

Conference abstract
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje et al.
Diabetelogia 2017;60:S300

Conference abstract
Modelling incremental benefits on macro- and micro-vascular complications rates when targeting lower systolic blood pressure levels in type 2 diabetes
S.A. Mostafa et al.
Diabetelogia 2017;60:S525

Conference abstract
Sensing hypoglycaemia at an earlier stage using an integrated physiological multi-signal data fusion approach
MJ Theodorakis et al.
Diabetic Medicine 2017;34 (Suppl 1):62-63